Cocrystal Pharma Inc. (COCP)
NASDAQ: COCPHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
COCP stock chart
Technical analysisKey statistics
All statistics- Market cap
- $20.61M
- EPS (TTM)
- -$0.76
- Dividend yield
- None
- 52-week range
- 0.76 – 2.03
- Day range
- 1.06 – 1.10
- Volume / Avg
- 29.03K / 56.00K
- Beta
- —
- Shares outstanding
- 19.26M
52-week range
COCP stock today
Cocrystal Pharma (COCP) closed at $1.07 on Oct 8, essentially unchanged from the prior close, versus the S&P 500's 0.47% decline. Shares are 47.3% below their 52-week high of $2.03, set on Apr 2, 2026 and 40.8% above the 52-week low of $0.76, in the middle of the past year's range. COCP is up 9.2% year to date, underperforming the S&P 500 (+13.5%). Over the past 12 months, the stock has lost 14.4%.
Cocrystal Pharma has posted a net loss over the last twelve months (EPS of -$0.76), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Cocrystal Pharma
Company profileCocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. James R. Sapirstein M.B.A., R.Ph.
- Headquarters
- Bothell, WA
- Employees
- 10
- Website
- cocrystalpharma.com
Analyst forecast
ForecastConsensus (1 analysts)
none
Avg. price target
$9.00+741.12%
- Strong buy 0
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Cocrystal Pharma peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| QNTMQuantum Biopharma Ltd. Class B Subordinate Voting Shares | 3.11 | -1.11% | $20.00M | vs COCP |
| PLRZPolyrizon Ltd. | 8.87 | -3.06% | $21.54M | vs COCP |
| QNRXQuoin Pharmaceuticals Ltd. ADR | 4.55 | -3.19% | $21.86M | vs COCP |
| JSPRJasper Therapeutics Inc. | 0.56 | -1.70% | $18.63M | vs COCP |
| AKTXAkari Therapeutics plc ADS | 8.13 | -5.74% | $18.58M | vs COCP |
| ICUSeaStar Medical Holding Corporation | 3.49 | -6.18% | $18.36M | vs COCP |
| ESLAEstrella Immunopharma Inc. | 0.4175 | -0.43% | $18.16M | vs COCP |
| NEUPNeuphoria Therapeutics Inc. | 3.35 | -2.05% | $18.13M | vs COCP |
Indexes, lists and sector
Appears in lists
Cocrystal Pharma stock FAQ
What is Cocrystal Pharma's stock price today?
COCP last traded at $1.07 as of Oct 8, 4:00 PM EDT, up 0.00% on the day. Prices are delayed at least 15 minutes.
Does Cocrystal Pharma pay a dividend?
No. Cocrystal Pharma does not currently pay a regular cash dividend.
Who is Cocrystal Pharma's CEO?
Mr. James R. Sapirstein M.B.A., R.Ph. is the chief executive officer of Cocrystal Pharma Inc., which has about 10 employees.
Has COCP ever split its stock?
Yes. The most recent COCP stock split was a 1-for-12 split on Oct 11, 2022, one of 2 splits on record.
What is the COCP 52-week high?
The 52-week high for COCP is $2.03 and the 52-week low is $0.76. The stock is currently 47.3% below its high.